Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

NCT00253214 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

973

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease
Dementia

Interventions

DRUG: galantamine hydrobromide

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.